Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Monopar Therapeutics Inc.
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
May 22, 2026
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
May 22, 2026
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
May 19, 2026